Skip to contentP
Protara Therapeutics, Inc.
P
TARAProtara Therapeutics, Inc. Q3 2017 · 10-Q
Revenue—
Net Income-$12.31M-$12.31MN/M vs Q3 2016 EPS Diluted-$1.08-$1.08N/M vs Q3 2016 Operating Income-$12,306,000N/M Operating Cash Flowderived-$5,926,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protara Therapeutics, Inc. · CIK 1359931 · Engraved from SEC EDGAR
Free Cash Flowderived-$5,935,000N/M ended Sep 30, 2017 · filed Nov 7, 2017 · 38 d after period end